LXN

LXN (Latexin) is a context-dependent intracellular and secreted regulator of cell proliferation, migration, and immune polarization that acts through distinct partner proteins and signaling axes in different cell types (PMID:23588494, PMID:36323670). In prostate epithelial cells LXN localizes to the nucleus and restrains colony formation and invasion, with its expression inducible by all-trans retinoic acid (PMID:23588494). Mechanistically, LXN engages discrete effectors depending on cellular context: it binds Filamin A and controls FLNA proteolytic cleavage and nuclear translocation to govern F-actin remodeling in endothelial cells (PMID:34085389); in smooth muscle cells it supports PDGF receptor expression to drive proliferation and migration, while in macrophages it promotes MCP-1-induced migration via ERK phosphorylation, and cell-type-specific deletion in SMCs and myeloid cells prevents neointimal hyperplasia. In macrophages LXN inhibits the JAK1/STAT3 axis to limit PD-L2 expression and is secreted in exosomes to suppress Treg differentiation, together restraining immunosuppression in the tumor microenvironment (PMID:36323670, PMID:39694381). In epithelial stem-cell and stress settings LXN is anti-proliferative or pro-senescent: its loss in intestinal stem cells activates YAP and Wnt signaling to expand Lgr5+ ISCs (PMID:39208900), whereas under oxalate stress in renal tubular epithelial cells it activates an Rps3/p53 pathway driving senescence, SASP secretion, and M1 macrophage polarization (PMID:41112268). LXN also operates in fibrogenesis through an LXN-THBS2 axis promoting hepatic stellate cell activation (PMID:41761978).

1. 2013 Medium

   Established LXN as a nuclear tumor-suppressor-like protein in epithelial cells, distinguishing its subcellular behavior and function from related factors and linking it to invasion and stem-cell properties.

   Evidence siRNA knockdown, subcellular fractionation/imaging, colony-forming and invasion assays in primary prostate cultures with atRA induction

   PMID:23588494

   Open questions at the time

   • No molecular partner or downstream effector identified for the nuclear suppressive activity
   • Mechanism of nuclear localization unresolved
2. 2021 Medium

   Identified a direct physical partner (Filamin A) and a cytoskeletal mechanism, explaining how LXN influences endothelial morphology and vascular biology.

   Evidence Co-IP/pulldown for LXN-FLNA interaction, F-actin imaging, and LXN-/- / ApoE-/-LXN-/- mouse vascular phenotyping

   PMID:34085389

   Open questions at the time

   • Whether LXN directly modulates the protease cleaving FLNA is unresolved
   • Reciprocal validation of interaction within the timeline limited to one study
3. 2022 Medium

   Placed LXN in a defined immune signaling pathway by showing it inhibits JAK1/STAT3 to limit PD-L2 and macrophage-driven T cell suppression in the tumor microenvironment.

   Evidence LXN-deficient mice, adoptive macrophage transfer rescue, JAK1/STAT3 assays, flow cytometry, tumor and AOM/DSS models with PD-L2 blockade

   PMID:36323670

   Open questions at the time

   • Direct biochemical engagement of JAK1 by LXN not structurally defined
   • Selectivity for PD-L2 over PD-L1 mechanistically unexplained
4. 2024 Medium

   Extended LXN's immune role to a secreted, exosome-delivered function that suppresses Treg differentiation, indicating both intracellular and extracellular modes of action.

   Evidence Macrophage-T cell co-culture, exosome isolation/characterization, flow cytometry, in vivo tumor models with LXN-loaded nanoparticles

   PMID:39694381

   Open questions at the time

   • Molecular target of secreted LXN on CD4+ T cells not identified
   • Mechanism of exosomal sorting of LXN unknown
5. 2024 Medium

   Revealed an anti-proliferative role in intestinal stem cells, linking LXN loss to YAP/Wnt activation and Lgr5+ ISC expansion.

   Evidence LXN-/- mice, intestinal organoids, siRNA, co-localization imaging, western blot for YAP/Wnt components

   PMID:39208900

   Open questions at the time

   • Direct molecular link between LXN and YAP/Wnt machinery not defined
   • Whether effect is cell-autonomous to ISCs unclear
6. 2024 Medium

   Defined cell-type-specific contributions to vascular remodeling, showing SMC and myeloid (not endothelial) LXN drives neointimal hyperplasia via PDGF-R and ERK signaling.

   Evidence Global and cell-type-specific LXN knockout mice, carotid artery ligation, proliferation/migration assays (preprint)

   Open questions at the time

   • Preprint; not yet peer-reviewed
   • Mechanism by which LXN supports PDGF-R expression not defined
7. 2024 Low

   Implicated LXN in proliferation/migration control of endometrial stromal cells, broadening its tissue contexts.

   Evidence siRNA knockdown, Transwell migration, MTT viability in endometrial stromal cells

   PMID:39202445

   Open questions at the time

   • No pathway placement or molecular mechanism
   • Single knockdown approach without orthogonal validation
8. 2025 Medium

   Identified an LXN/Rps3/p53 senescence pathway linking oxidative stress in renal epithelium to inflammatory macrophage polarization and crystal deposition.

   Evidence siRNA and AAV-mediated silencing in rat, SA-β-gal staining, SASP measurement, macrophage co-culture

   PMID:41112268

   Open questions at the time

   • Direct biochemical interaction of LXN with Rps3/p53 not shown
   • Generality beyond oxalate-induced stress untested
9. 2026 Medium

   Defined an LXN-THBS2 axis in hepatic stellate cell activation and liver fibrosis, adding a fibrogenic role.

   Evidence AAV9-mediated LXN knockdown in mouse fibrosis model, siRNA in LX-2 cells, qPCR/western/IHC

   PMID:41761978

   Open questions at the time

   • Whether LXN regulates THBS2 directly or indirectly unresolved
   • No physical interaction demonstrated

• How a single protein executes opposite (suppressive vs. pro-proliferative/pro-senescent) functions across cell types, and whether its reported carboxypeptidase-inhibitory activity underlies any of these signaling roles, remains unresolved.
• No unifying biochemical mechanism reconciling context-specific roles
• Enzymatic/inhibitory activity not connected to documented signaling phenotypes in the corpus